There is no evidence of serious deficiencies in an NIH – funded study of the antiretroviral drug nevirapine among pregnant women in Uganda, the doubt would on the results of the study, according to a report on Thursday by an independent review panel. The Institute of Medicine, the Baltimore Sun reports publishes the IOM panel for the study. Called HIVNET 012. Which in 1997 started the use of single-dose nevirapine in HIV-positive pregnant women in Uganda, prevent vertical HIV transmission study the first results showed that the drug HIV transmission can be prevented to newborns in as many as half of all births. However, by early 2002, cited health safety specialists and auditors with NIH and the drug manufacturer, Boehringer Ingelheim, in 2004,trative problems with the research in Uganda.

###The ongoing research Getz Getz Family Fund for Mantle Cell Lymphoma Research, the rich family funds for Lymphoma Research and the Lowell and Rebecca Whitlock Fund for Mantle Cell Lymphoma Research.For summer adults adults in that showing Americans emphatically support guaranteed to dental coverage in health reforms.

In June, Oral Health America, National Museum of Dentistry, Hispanic Dental Association, dental offices, community care party, schools camps and celebrating Domestic smiling Month and encouraging families not forgotten their tooth brushes on vacation.